|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.070 USD | -4.20% |
|
+27.16% | +221.36% |
| Dec. 09 | Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants | RE |
| Dec. 08 | Immix Biopharma Prices $100 Million Offering | MT |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Assets | ||||||
Cash And Equivalents | 391K | 17.64M | 13.44M | 17.51M | 17.68M | |
Total Cash And Short Term Investments | 391K | 17.64M | 13.44M | 17.51M | 17.68M | |
Other Receivables | 297K | 25.72K | 256K | 1.17M | 1.97M | |
Total Receivables | 297K | 25.72K | 256K | 1.17M | 1.97M | |
Prepaid Expenses | 14.72K | 516K | 1.21M | 1.06M | 509K | |
Other Current Assets, Total | - | - | - | 44.58K | 32.27K | |
Total Current Assets | 703K | 18.19M | 14.9M | 19.79M | 20.2M | |
Gross Property Plant And Equipment | - | - | - | - | 2.78M | |
Accumulated Depreciation | - | - | - | - | -47.26K | |
Net Property Plant And Equipment | 7.36K | 5.7K | 3.56K | 50.18K | 2.73M | |
Deferred Charges Long-Term | - | - | - | 87.23K | - | |
Other Long-Term Assets, Total | - | - | 6.72K | - | 20.42K | |
Total Assets | 710K | 18.19M | 14.91M | 19.93M | 22.95M | |
Liabilities | ||||||
Accounts Payable, Total | 263K | 143K | 1.27M | 1.43M | 5.39M | |
Accrued Expenses, Total | 343K | 9.1K | - | 2.29M | 3.23M | |
Short-term Borrowings | 4.1M | 50K | - | - | - | |
Current Portion of Leases | - | - | - | - | 65.22K | |
Other Current Liabilities | 575K | - | - | - | - | |
Total Current Liabilities | 5.28M | 202K | 1.27M | 3.72M | 8.69M | |
Long-Term Leases | - | - | - | - | 1.01M | |
Other Non Current Liabilities | - | - | 475K | - | - | |
Total Liabilities | 5.28M | 202K | 1.75M | 3.72M | 9.7M | |
Common Stock, Total | 113 | 1.32K | 1.4K | 2K | 2.76K | |
Additional Paid In Capital | 509K | 47.62M | 51.16M | 69.78M | 88.37M | |
Retained Earnings | -5.23M | -29.76M | -37.99M | -53.41M | -75.02M | |
Treasury Stock | - | - | -99.96K | -99.96K | -99.96K | |
Comprehensive Income and Other | 148K | 125K | 87.02K | 135K | -1.06K | |
Total Common Equity | -4.57M | 17.99M | 13.16M | 16.41M | 13.25M | |
Minority Interest | - | - | - | -202K | - | |
Total Equity | -4.57M | 17.99M | 13.16M | 16.2M | 13.25M | |
Total Liabilities And Equity | 710K | 18.19M | 14.91M | 19.93M | 22.95M | |
Supplemental Items | ||||||
ECS Total Shares Outstanding on Filing Date | 3.38M | 13.86M | 13.9M | 26.4M | 27.72M | |
ECS Total Common Shares Outstanding | 3.38M | 13.23M | 13.89M | 19.92M | 27.54M | |
Book Value / Share | -1.35 | 1.36 | 0.95 | 0.82 | 0.48 | |
Tangible Book Value | -4.57M | 17.99M | 13.16M | 16.41M | 13.25M | |
Tangible Book Value Per Share | -1.35 | 1.36 | 0.95 | 0.82 | 0.48 | |
Total Debt | 4.1M | 50K | 0 | 0 | 1.07M | |
Net Debt | 3.71M | -17.59M | -13.44M | -17.51M | -16.61M | |
Debt Equivalent Oper. Leases | - | - | - | - | 1.8M | |
Minority Interest, Total (Incl. Fin. Div) | - | - | - | -202K | - | |
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |
Machinery, Total | - | - | - | - | 849K | |
Full Time Employees | - | 2 | 9 | 14 | 18 | |
Part Time Employees | - | - | 2 | 3 | 3 |
Select your edition
All financial news and data tailored to specific country editions
















